1
Clinical Trials associated with Recombinant aiti-RANKL human monoclonal antibody(Shanghai Hansoh Biomedical Co. Ltd.)在健康受试者中评价HS-20090-2注射液比对Prolia注射液在药代动力学、安全性和免疫原性上的随机、平行对照的I期临床研究
[Translation] A randomized, parallel-controlled phase I clinical study to evaluate the pharmacokinetics, safety, and immunogenicity of HS-20090-2 injection versus Prolia injection in healthy subjects
主要研究目的:
评价候选药HS-20090-2和参照药Prolia在药代动力学上的相似性。
次要研究目的:
评价候选药HS-20090-2和参照药Prolia在安全性上的相似性;
评价候选药HS-20090-2和参照药Prolia在免疫原性上的相似性。
[Translation] Primary study objectives:
To evaluate the pharmacokinetic similarity between the candidate drug HS-20090-2 and the reference drug Prolia.
Secondary study objectives:
To evaluate the safety similarity between the candidate drug HS-20090-2 and the reference drug Prolia;
To evaluate the immunogenicity similarity between the candidate drug HS-20090-2 and the reference drug Prolia.
100 Clinical Results associated with Recombinant aiti-RANKL human monoclonal antibody(Shanghai Hansoh Biomedical Co. Ltd.)
100 Translational Medicine associated with Recombinant aiti-RANKL human monoclonal antibody(Shanghai Hansoh Biomedical Co. Ltd.)
100 Patents (Medical) associated with Recombinant aiti-RANKL human monoclonal antibody(Shanghai Hansoh Biomedical Co. Ltd.)
100 Deals associated with Recombinant aiti-RANKL human monoclonal antibody(Shanghai Hansoh Biomedical Co. Ltd.)